Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.40
Bid: 9.32
Ask: 9.48
Change: 0.00 (0.00%)
Spread: 0.16 (1.717%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.40
OBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

1 Nov 2018 17:17

RNS Number : 1085G
Oxford BioDynamics PLC
01 November 2018
 

 

OXFORD BIODYNAMICS PLC

 

 

TOTAL VOTING RIGHTS

 

 

London, 1 November 2018: Oxford BioDynamics Plc (AIM: OBD) (the "Company")

 

In conformity with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company notifies the market that as at 31 October 2018 the Company's total issued share capital consisted of 92,546,138 ordinary shares with one voting right per share. The Company does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in the Company is 92,546,138.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further details, contact:

 

Oxford BioDynamics Plc

+44 (0)1865 518910

Christian Hoyer Millar, CEO

Paul Stockdale, CFO

Shore Capital

+44 (0)20 7408 4090

Nominated Advisor and Broker

Stephane Auton

Edward Mansfield

FTI Consulting

+44 (0)20 3727 1000

Financial Public Relations Advisor

Brett Pollard

Natalie Garland-Collins

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRMMMGMNMDGRZM
Date   Source Headline
27th Mar 20242:18 pmRNSResult of AGM
14th Mar 20247:00 amRNSResults of Fundraising
13th Mar 20244:45 pmRNSPrimaryBid Offer
13th Mar 20244:40 pmRNSProposed Fundraising
22nd Feb 20242:30 pmRNSAnnual Report & Accounts
17th Jan 20247:00 amRNSPreliminary Results and Notice of AGM
21st Dec 20237:20 amRNSNotice of Results
13th Nov 202310:22 amRNSDirector/PDMR Shareholding
8th Nov 20237:00 amRNSOBD strengths commercial leadership
7th Nov 202312:30 pmRNSHolding(s) in Company
6th Nov 20235:04 pmRNSHolding(s) in Company
3rd Nov 20239:29 amRNSDirector/PDMR Shareholding
23rd Oct 202311:09 amRNSPDMR Dealing / Grant of Share Options
20th Oct 20239:45 amRNSDirector/PDMR Shareholding
18th Oct 20237:00 amRNSBupa UK to cover EpiSwitch® CiRT for customers
6th Oct 20235:44 pmRNSDirector/PDMR Shareholding
3rd Oct 20234:37 pmRNSHolding(s) in Company
3rd Oct 20237:00 amRNSOBD receives reimbursement code for PSE test
26th Sep 20237:00 amRNSOBD launches 94% accurate PSE test in US and UK
7th Sep 202310:18 amRNSHolding(s) in Company
1st Sep 202312:34 pmRNSAmendment: Director/PDMR Shareholding
31st Aug 20234:02 pmRNSHolding(s) in Company
25th Aug 20239:00 amRNSHolding(s) in Company
22nd Aug 20233:58 pmRNSHolding(s) in Company
22nd Aug 20237:00 amRNSHolding(s) in Company
22nd Aug 20237:00 amRNSHolding(s) in Company
18th Aug 202311:44 amRNSResult of General Meeting
8th Aug 20234:00 pmRNSHolding(s) in Company
4th Aug 20237:00 amRNSResults of PrimaryBid Offer
2nd Aug 20237:00 amRNSResult of Placing and Subscription
1st Aug 20234:55 pmRNSPrimaryBid Offer
1st Aug 20234:54 pmRNSProposed Fundraising
30th May 20237:00 amRNSHalf-year Report
16th May 20237:00 amRNSNotice of Interim Results and Investor Webinar
15th May 20237:00 amRNSCiRT expanded validation for ICI immunotherapies
2nd May 20237:00 amRNSUS PACT Award for prognosis test for IOrelated HPD
18th Apr 20237:00 amRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSBusiness update for PSE and CiRT tests
30th Mar 20231:04 pmRNSResult of AGM
23rd Mar 20233:19 pmRNSHolding(s) in Company
22nd Mar 20232:22 pmRNSHolding(s) in Company
15th Mar 202311:43 amRNSAIM Rule 17 Schedule 2(g) Update
3rd Mar 20234:33 pmRNSPublication of FY22 Annual Report
23rd Feb 202310:36 amRNSPDMR Dealing
6th Feb 20237:00 amRNSOBD Prostate Screening EpiSwitch Blood Test Update
27th Jan 20232:36 pmRNSDirector/PDMR Shareholding
24th Jan 20237:00 amRNSPreliminary Results and Notice of AGM
21st Dec 20227:00 amRNSNotice of FY22 Results and Investor Webinar
19th Dec 20227:00 amRNSOBD in San Francisco for JPM Healthcare conf 2023
16th Dec 20227:00 amRNSInitial assessment of EpiSwitch assay in ALS trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.